title: Adverse impact of venous thromboembolism on patients with cancer.
abstract: Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California.
authors.forename: Mili
authors.initials: M
authors.lastname: Arora
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California.
authors.forename: Ted
authors.initials: T
authors.lastname: Wun
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D016019:Survival Analysis; D054556:Venous Thromboembolism / Q000150:complications* / Q000503:physiopathology